TY - JOUR
T1 - Data of a meta-analysis on pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia
AU - Labad, Javier
AU - Montalvo, Itziar
AU - González-Rodríguez, Alexandre
AU - García-Rizo, Clemente
AU - Crespo-Facorro, Benedicto
AU - Monreal, José Antonio
AU - Palao, Diego
N1 - Funding Information:
Javier Labad and Itziar Montalvo have received an Intensification of the Research Activity Grant by the Health Department from the Generalitat de Catalunya (SLT006/17/00012 and SLT008/18/00074). Javier Labad has received an Intensification of the Research Activity Grant by the Instituto de Salud Carlos III (INT19/00071).
PY - 2020/8/1
Y1 - 2020/8/1
N2 - The data presented in this paper describe supplementary material to the article entitled “Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: a systematic review and meta-analysis” [1]. Although raw data was published on the original article, additional raw data has been included in the current paper (new tables with socio-demographic and clinical characteristics of the samples of the studies included in the systematic review). Supplementary data also include the PICO scheme of the systematic review, PRISMA checklist, flow diagram, an explanation of the method for obtaining prolactin concentrations from published figures when data was only available in figures, list of the selected studies, risk of bias summary of all five randomized clinical trials evaluating the addition of aripiprazole for lowering prolactin (included in the meta-analysis in the original article). Extra analyses, figures and R code of the meta-analysis have been also included. Meta-analysis of randomized clinical trials (RCTs) considering aripiprazole addition for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia were conducted with two softwares: 1) R and the metaphor package (for the meta-analysis of the primary outcome [prolactin reduction]); 2) MedCalc version 18.11 (for the meta-analysis of the secondary outcome [withdrawal rates]). Data from a sensitivity analysis (repeating the meta-analysis with only placebo-controlled RCTs) has been also included in the current article.
AB - The data presented in this paper describe supplementary material to the article entitled “Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: a systematic review and meta-analysis” [1]. Although raw data was published on the original article, additional raw data has been included in the current paper (new tables with socio-demographic and clinical characteristics of the samples of the studies included in the systematic review). Supplementary data also include the PICO scheme of the systematic review, PRISMA checklist, flow diagram, an explanation of the method for obtaining prolactin concentrations from published figures when data was only available in figures, list of the selected studies, risk of bias summary of all five randomized clinical trials evaluating the addition of aripiprazole for lowering prolactin (included in the meta-analysis in the original article). Extra analyses, figures and R code of the meta-analysis have been also included. Meta-analysis of randomized clinical trials (RCTs) considering aripiprazole addition for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia were conducted with two softwares: 1) R and the metaphor package (for the meta-analysis of the primary outcome [prolactin reduction]); 2) MedCalc version 18.11 (for the meta-analysis of the secondary outcome [withdrawal rates]). Data from a sensitivity analysis (repeating the meta-analysis with only placebo-controlled RCTs) has been also included in the current article.
KW - Antipsychotics
KW - Aripiprazole
KW - Dopamine agonists
KW - Hyperprolactinaemia
KW - Schizophrenia
KW - Switching
UR - http://www.scopus.com/inward/record.url?scp=85087289182&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/8e6fb0ae-4690-3a3e-942e-c71936071423/
U2 - 10.1016/j.dib.2020.105904
DO - 10.1016/j.dib.2020.105904
M3 - Artículo
C2 - 32642517
AN - SCOPUS:85087289182
SN - 2352-3409
VL - 31
SP - 105904
JO - Data in brief
JF - Data in brief
M1 - 105904
ER -